Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? The clinical practice
Kristjan Karason discusses hospitalised acute heart failure patients from the EuroHeart Failure Survey II (EHFS II), the 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. He also looks at the 3 mechanisms of action of levosimendan and how it’s considered in treatment.
Zoltán Papp looks at the current management of acute heart failure and the 2016 ESC guidelines and the inotropic agents dobutamine, dopamine, levisomendan and phosphodiesterase III (PDE III) inhibitors.